INFevo, AI-Powered Virtual Cell Platform Incubated by XtalPi, Secures Tens of Millions in Angel Funding to Accelerate Novel Target Discovery and Clinical Translation

XtalPi: An AI- and Robotics-Driven Platform Enterprise for R&D Innovation (2228.HK) announced today that its deeply incubated frontier AI biotech enterprise, INFevo, has completed a tens-of-millions-yuan angel financing round, with participation from Shunwei Capital, HongShan, and Green Pine Capital. INFevo focuses on building an AI-based “Virtual Cell System,” aiming to deeply decode the language of life, thereby precisely guiding innovative drug discovery and engineered cell design.

Currently, biomedical R&D is universally plagued by the dilemma of extremely low clinical translation rates. In complex fields such as central nervous system disorders, immune diseases, and anti-aging, R&D success rates have long hovered between 5% and 8%. The root cause lies in the industry’s persistent lack of research systems capable of representing and predicting the complexities of human physiology; significant species differences between animal models and humans lead to the failure of numerous candidate molecules in late-stage clinical trials. The key to resolving this challenge lies in shifting from static structural understanding to dynamic systems-level research. The scientific community widely recognizes that constructing high-fidelity virtual cells is the critical technology for bridging the predictive gap from the laboratory to the human body through system-level quantitative simulation.

To achieve this goal, INFevo adopts a dual-drive strategy of “full-stack AI foundation models + high-throughput automated experiments.” By establishing digital models capable of predicting cell state evolution under genetic, chemical, and environmental perturbations, and forming a self-reinforcing “dry-wet closed loop,” INFevo accelerates the transformation of virtual cells from a scientific concept into an industrial-grade, high-efficiency R&D tool.

Since its inception, INFevo has upheld a global business vision, directly addressing the core pain points in drug development, and has assembled a cross-disciplinary team that combines robust foundational scientific capabilities with industrial delivery experience.

As a strategic project incubated internally by XtalPi, INFevo achieves a high degree of synergy with XtalPi across the drug innovation value chain. XtalPi possesses efficient “molecule-level” and “structure-level” design and screening capabilities in fields such as small molecules, large molecules, peptides, and nucleic acids, while INFevo provides AI models and translational predictions at the “cellular level” and “systems biology level.” The integration of these two entities promises to bridge the long-standing gap between molecular optimization and translational prediction within the drug discovery pipeline for the first time, significantly deepening the competitive moat for both parties.

Leveraging XtalPi’s industry expertise as a leading listed technology company, its robust engineering delivery infrastructure, and global industrial resources, INFevo has rapidly transcended the platform-building phase typical of startups. By capitalizing on China’s abundant scientific research and multidimensional clinical data resources, the company is poised to accelerate the realization of a complete closed loop—from frontier technological innovation to global commercial implementation. Through the construction of virtual cell models based on AI+Biology large models, and in collaboration with global pharmaceutical and biotechnology partners, INFevo aims to jointly explore the “boundless evolution” of life sciences.

● GuanatINFevo●

Beijing INFevo Technology Co., Ltd. (INFevo) is dedicated to building industry-leading AI virtual cell models, providing transformative biological research tools for global drug innovation. By integrating its proprietary state-of-the-art (SOTA) foundational large model, OCOO, with an automated and intelligent cellular experimental platform, the company has created a globally leading biopharmaceutical innovation research platform for the AI era, thereby strongly supporting breakthroughs in basic biological research. Furthermore, the company accelerates the translation of innovative achievements into practical applications by effectively bridging clinical research. Focusing on challenging therapeutic areas such as anti-aging, neurodegenerative diseases, autoimmune disorders, metabolic diseases, and oncology, INFevo is rapidly establishing a comprehensive AI biology platform that covers new mechanism and target discovery, virtual drug screening and evaluation, and clinical protocol optimization.